Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557239 | 0.86 | CYP2C19 (0.34) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL3019549 | 0.82 | — | — | |
| SCHEMBL1968142 | 0.79 | KDM4E (0.43) | HSD17B10 | |
| SCHEMBL322137 | 0.77 | — | — | |
| SCHEMBL2941358 | 0.77 | CYP2C19 (0.52) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL2012393 | 0.76 | TSHR (0.38) | CYP2C19HSD17B10TSHRCYP1A2LMNA | |
| SCHEMBL304486 | 0.75 | CYP2C19 (0.56) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL27683934 | 0.75 | CYP2C19 (0.56) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL1555451 | 0.75 | CYP2C19 (0.56) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL6594726 | 0.74 | TSHR (0.38) | CYP2C19HSD17B10TSHRCYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2680840-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8598357-B2 | Benzodioxole piperidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2334657-B1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| WO-2012117001-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20120225868-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2334657-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-7858630-B2 | D3 and 5-HT2A receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010031735-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| CN-1972920-A | Arylalkyl piperazine derivatives for the treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms | WYETH CORP (US) | 2007-05-30 | — | — | CN | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| CN-1897946-A | 1- 2' (1, 4'-biperidin-1'-yl)-1- (phenyl) -ethyl cyclohexanol derivatives as monoamine reuptake modulators for the treatment of visomotor symptoms | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1894226-A | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH CORP (US) | 2007-01-10 | — | — | CN | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | CYP2C19 290/4885HSD17B10 280/4885TSHR 2647/4885 |
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | CYP2C19 151/4885HSD17B10 1985/4885TSHR 933/4885 |
| US-20120225868-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | HTR2A, HTR2C, HTR1D | CYP2C19 143/4885HSD17B10 1604/4885TSHR 313/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | CYP2C19 2407/4885HSD17B10 1713/4885TSHR 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.